Tonjanika Boyd
Psychiatric/Mental Health · Richmond, VANPI 1255717088
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 90.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $14,468 and has fallen 94.6% since, to $786 in 2025. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $228.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$36K
- Otsuka America Pharmaceutical, Inc.$824
- Teva Pharmaceuticals USA, Inc.$585
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$526
- Johnson & Johnson$362
- AbbVie$291
- plus $1K from 13 others
What the payments were for
- Consulting fees$10,12625%
- Speaking & faculty fees$21,57854%
- Travel & lodging$2,4816%
- Food & beverage$5,73614%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$35,177
- ABILIFY MAINTENA$242
- REXULTI$237
- INVEGA SUSTENNA$230
- AUSTEDO$200
- VRAYLAR$125
- ABILIFY ASIMTUFII$125
- Austedo XR$125
- CAPLYTA$124
- Dyanavel XR$122
- Quillichew ER$122
- Quillivant$122
- SUNOSI$122
How this compares
$39,966 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $116,425 |
| AustedoDeutetrabenazine | 15 | $91,474 |
| Invega SustennaPaliperidone Palmitate | 20 | $74,824 |
| RexultiBrexpiprazole | 31 | $46,130 |
| AdderallDextroamphetamine/Amphetamine | 14 | $9,017 |
| Lurasidone Hcl | 52 | $7,309 |
| Paliperidone ErPaliperidone | 19 | $6,347 |
| Olanzapine | 213 | $3,780 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 64 | $3,152 |
| Clozapine | 41 | $3,087 |
| Aripiprazole | 87 | $3,002 |
| Divalproex Sodium | 137 | $2,701 |
| Ziprasidone Hcl | 36 | $2,586 |
| Divalproex Sodium ErDivalproex Sodium | 61 | $1,887 |
| Oxcarbazepine | 19 | $1,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $36,209 | $116,42515 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $585 | $91,47415 claims |
| Johnson & JohnsonInvega Sustenna | $362 | $74,82420 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $824 | $46,13031 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $132 | $9,01714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Richmond
- Kirby PatmonRichmond$36K
- Abbie SmithRichmond$14K
- Thomas MamalakisRichmond$12K
- Monica MeyerRichmond$11K
- Vicky SpillerRichmond$10K
- Kimberly Southam-GerowRichmond$8K
- Charles McDonoughRichmond$7K
- Nympha DalgadoRichmond$7K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.